AR037038A1 - Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto - Google Patents

Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto

Info

Publication number
AR037038A1
AR037038A1 ARP020104067A ARP020104067A AR037038A1 AR 037038 A1 AR037038 A1 AR 037038A1 AR P020104067 A ARP020104067 A AR P020104067A AR P020104067 A ARP020104067 A AR P020104067A AR 037038 A1 AR037038 A1 AR 037038A1
Authority
AR
Argentina
Prior art keywords
subject
ghrh
increase
cells
functional biological
Prior art date
Application number
ARP020104067A
Other languages
English (en)
Inventor
Ruxandra Draghia-Akli
Robert J Schwartz
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of AR037038A1 publication Critical patent/AR037038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente corresponde a un método para disminuir la proporción de grasa corporal, incrementar la masa corporal magra (''LBM''), incrementar la densidad ósea o mejorar la velocidad de curado óseo o todos en un sujeto. Todas las realizaciones de la presente pueden ser llevadas a cabo mediante la liberación de secuencias de ácido nucleico heterólogas que codifican GHRH ó un equivalente biológico funcional de la misma dentro de las células de un sujeto y permitir la expresión del gen codificado mientras las células modificadas se encuentran dentro del sujeto. Por ejemplo, cuando tal secuencia de ácido nucleico es liberada dentro de células específicas del tejido del sujeto, se lleva a cabo la expresión específica constitutiva. Además, se puede llevar a cabo la regulación externa del gen de GHRH ó el equivalente biológico funcional del mismo mediante la utilización de promotores inducibles que son regulados por moléculas interruptor molecular, que son administradas al sujeto. El método preferido para liberar la secuencia codificante de ácido nucleico inducible o constitutiva de GHRH ó los equivalentes biológicos funcionales de la misma es dirigirla dentro de las células del sujeto mediante el proceso de electroporación in vivo. Se lleva a cabo una disminución de la proporción de grasa corporal y un incremento de la masa corporal magra (''LBM''), o ambas en un sujeto mediante la liberación de GHRH o el equivalente biológico funcional de la misma tal como se describe aquí introduciéndole al sujeto proteínas recombinantes. Además, se lleva a cabo un incremento en la densidad ósea y un mejoramiento en la velocidad de curado óseo.
ARP020104067A 2001-10-26 2002-10-25 Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto AR037038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35780801P 2001-10-26 2001-10-26

Publications (1)

Publication Number Publication Date
AR037038A1 true AR037038A1 (es) 2004-10-20

Family

ID=23407110

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104067A AR037038A1 (es) 2001-10-26 2002-10-25 Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto

Country Status (10)

Country Link
US (2) US7338656B2 (es)
EP (1) EP1450605B1 (es)
CN (1) CN100417419C (es)
AR (1) AR037038A1 (es)
AT (1) ATE536100T1 (es)
AU (1) AU2002348417B9 (es)
BR (1) BR0213965A (es)
CA (1) CA2464199C (es)
MX (1) MXPA04003944A (es)
WO (1) WO2003038112A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
US7493171B1 (en) * 2000-11-21 2009-02-17 Boston Scientific Neuromodulation Corp. Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion
US7440806B1 (en) * 2000-11-21 2008-10-21 Boston Scientific Neuromodulation Corp. Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
WO2003023000A2 (en) * 2001-09-07 2003-03-20 Baylor College Of Medicine Linear dna fragments for gene expression
TW200307749A (en) * 2002-02-07 2003-12-16 Baylor College Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
WO2005073371A2 (en) * 2004-01-20 2005-08-11 Advisys, Inc. Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
CN1313494C (zh) * 2005-08-29 2007-05-02 中国人民解放军军事医学科学院生物工程研究所 一种具有促增长作用的融合蛋白及其编码基因与应用
JP5032500B2 (ja) * 2006-01-03 2012-09-26 アルコン，インコーポレイティド 蛋白性組織の解離及び除去のためのシステム
US20110118729A1 (en) * 2009-11-13 2011-05-19 Alcon Research, Ltd High-intensity pulsed electric field vitrectomy apparatus with load detection
US20110118734A1 (en) * 2009-11-16 2011-05-19 Alcon Research, Ltd. Capsularhexis device using pulsed electric fields
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
US20110144562A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields
US20110144641A1 (en) * 2009-12-15 2011-06-16 Alcon Research, Ltd. High-Intensity Pulsed Electric Field Vitrectomy Apparatus
US8546979B2 (en) 2010-08-11 2013-10-01 Alcon Research, Ltd. Self-matching pulse generator with adjustable pulse width and pulse frequency
US20130261058A1 (en) * 2010-09-16 2013-10-03 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
CN105671139A (zh) * 2014-11-17 2016-06-15 武汉白原科技有限公司 人体lbm（瘦体重）检测试剂盒和方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US5134120A (en) 1984-08-03 1992-07-28 Cornell Research Foundation, Inc. Use of growth hormone to enhance porcine weight gain
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4833166A (en) 1987-05-01 1989-05-23 Grosvenor Clark E Growth hormone releasing hormone complementary peptides
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
USRE33699E (en) 1987-07-09 1991-09-24 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
FR2622455B1 (fr) 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
WO1991011522A1 (en) 1990-01-26 1991-08-08 Baylor College Of Medicine MUTATED PROMOTER REGION FROM CHICKEN SKELETAL α-ACTIN GENE
EP0544706A4 (en) 1990-06-29 1993-10-13 Hoffmann-La Roche Inc. Histidine substituted growth hormone releasing factor analogs
US5486505A (en) 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
EP0542937A1 (en) 1991-04-09 1993-05-26 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
DE69333434T2 (de) 1992-04-03 2005-03-03 The Regents Of The University Of California, Oakland Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5507724A (en) 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル，インコーポレイテッド 培養ダイズ細胞のａｇｒｏｂａｃｔｅｒｉｕｍ媒介形質転換の改良法
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5655961A (en) 1994-10-12 1997-08-12 Acres Gaming, Inc. Method for operating networked gaming devices
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
AU5441096A (en) 1995-04-14 1996-10-30 The Administrators Of The Tulane Eductional Fund Analogs of growth hormone-releasing factor
WO1997007826A1 (en) 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
US6165755A (en) * 1997-01-23 2000-12-26 University Of Victoria Innovation And Development Corporation Chicken neuropeptide gene useful for improved poultry production
US6423693B1 (en) * 1997-07-24 2002-07-23 Baylor College Of Medicine Growth hormone releasing hormone expression system and methods of use, including use in animals
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
BR0012748A (pt) 1999-07-26 2003-06-10 Baylor College Of Medcine Análogo super-ativo do hormÈnio de lberação do hormõnio do crescimento porcino
US6486134B2 (en) * 1999-09-17 2002-11-26 Leadergene Limited Gene treatment to enhance feed efficiency and growth rate of livestock
BR0108962A (pt) * 2000-03-03 2002-12-24 Valentis Inc Formulações de ácido nucléico para distribuição de genes e métodos de uso
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
AR035671A1 (es) 2000-12-12 2004-06-23 Advisys Inc Administracion de secuencia de acido nucleico a un animal hembra, para aumentar el crecimiento de la descendencia
US7241744B2 (en) * 2001-12-11 2007-07-10 Baylor College Of Medicine Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone
US9302725B2 (en) 2013-03-14 2016-04-05 Bell Sports, Inc. Locking rack system for bicycles
WO2015178959A1 (en) 2014-05-19 2015-11-26 Felix Sorkin Modified permanent cap

Also Published As

Publication number Publication date
CN1649496A (zh) 2005-08-03
EP1450605A2 (en) 2004-09-01
BR0213965A (pt) 2005-03-15
WO2003038112A3 (en) 2003-11-06
AU2002348417B9 (en) 2010-02-04
US20040138111A1 (en) 2004-07-15
ATE536100T1 (de) 2011-12-15
WO2003038112A2 (en) 2003-05-08
MXPA04003944A (es) 2004-07-08
CN100417419C (zh) 2008-09-10
CA2464199C (en) 2013-12-24
WO2003038112B1 (en) 2004-04-08
US7338656B2 (en) 2008-03-04
EP1450605A4 (en) 2007-01-17
CA2464199A1 (en) 2003-05-08
AU2002348417B2 (en) 2009-10-01
US20090292107A1 (en) 2009-11-26
EP1450605B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
AR037038A1 (es) Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
FR15C0003I2 (fr) Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines
ES2620258T3 (es) Método de tratamiento de células madre mesenquimales y su uso en el tratamiento de enfermedades asociadas con el estrés oxidativo
IL144446A0 (en) Plasma protein matrices and methods for their preparation
ES2534724T3 (es) Células madre hematopoyéticas adecuadas para el trasplante, su preparación y composiciones farmacéuticas que las comprenden
ATE540973T1 (de) Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
EE200100149A (et) Meetod osteoprotegeriini ligandi (OPGL) in vivo toime mahasurumiseks loomorganismil, OPGL analoog, seda sisaldav immunogeenne kompositsioon ning meetod selle valmistamiseks
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
RU2006107536A (ru) Применение хемокина cxcl6 для предотвращения или восстановления хрящевых дефектов
US11773376B2 (en) Artificial tendon or ligament tissue produced using three-dimensional mechanosignaling cell culture system
HUP9904219A2 (hu) Eljárás és készítmények interferon-alfa-nukleinsavak bevitelére és expressziójára
WO2002050111A3 (en) Isolated laminin 10
JP2008542339A (ja) 間葉系幹細胞の増殖を刺激するオリゴヌクレオチド及びその使用
WO2004050844A3 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
EP2322604A1 (en) Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1
WO2002068629A3 (en) Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same
CN1853609A (zh) 酸性纤维母细胞生长因子（fgf－1）应用于护肤功效
CN201271394Y (zh) 生物型鼻梁植入体
Nigmatov MODERN TREATMENT AND CORRECTION OF THE CONSEQUENCES OF LOCALIZED SCLERODERMA
TH78121A (th) สารผสมและวิธีเปลี่ยนแปลงมวลร่างกายในคนผอมและคุณสมบัติของกระดูกในผู้เข้ารับการทดลอง
RU2628706C2 (ru) Способ стимуляции ангиогенеза в ишеминизированных тканях и комбинированное лекарственное средство для осуществления способа
TH78121B (th) สารผสมและวิธีเปลี่ยนแปลงมวลร่างกายในคนผอมและคุณสมบัติของกระดูกในผู้เข้ารับการทดลอง
CN117545507A (zh) 生化激活功能障碍骨骼干细胞以实现骨骼再生

Legal Events

Date Code Title Description
FB Suspension of granting procedure